The present analysis provides an estimate of the average treatment effects of testosterone therapy in middle-aged men .
OBJECTIVES Ageing in men is associated with a gradual decline in serum testosterone levels and a concomitant loss of muscle mass , accumulation of central adiposity , impaired mobility and increased risk of bone fractures .
Whether and rogen treatment might be beneficial in these subjects is still under debate .
We have carried out a systematic review of r and omized controlled trials ( RCTs ) evaluating the effects of testosterone ( T ) administration  to middle-aged and ageing men on body composition , muscle strength , bone density , markers of bone metabolism and serum lipid profile .
A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis.
We conducted a prospect i ve , r and omized study in chronic hemodialysis patients in order to determine whether the erythropoietic response to low dose recombinant human erythropoietin ( rHuEpo ) could be enhanced by administration with and rogens . Patients received rHuEpo 40 U/kg intravenously three times weekly either alone  ( Group 1 , n = 6 ) or with weekly intramuscular injection of 2 mg/kg n and rolone decanoate  ( Group 2 , n = 6 ) for up to 16 weeks . Baseline hct , ferritin , N-terminal parathyroid hormone , and aluminum levels were similar . The mean weekly rate of rise in hct was 0.32 + /- 0.13 % in Group 1 and 0.37 + /- 0.11 % in Group 2 , p = NS . Three of 6 patients in Group 1 , but only 1 of 6 patients in Group 2 , reached the target hct of 30 % within 16 weeks . Two patients in Group 2 requested that the n and rolone decanoate be stopped prior to reaching target hct because of unacceptable side effects ( acne ) . We conclude that many chronic hemodialysis patients appear to respond adequately to rHuEpo at the dose used in our study . N and rolone decanoate does not enhance the response rate to this rHuEpo dose and is associated with significant side effects
The present analysis provides an estimate of the average treatment effects of testosterone therapy in middle-aged men .
OBJECTIVES Ageing in men is associated with a gradual decline in serum testosterone levels and a concomitant loss of muscle mass , accumulation of central adiposity , impaired mobility and increased risk of bone fractures .
Whether and rogen treatment might be beneficial in these subjects is still under debate .
We have carried out a systematic review of r and omized controlled trials ( RCTs ) evaluating the effects of testosterone ( T ) administration  to middle-aged and ageing men on body composition , muscle strength , bone density , markers of bone metabolism and serum lipid profile .